Epizyme, Inc. (NASDAQ:EPZM) – Equities research analysts at SunTrust Banks increased their FY2017 earnings per share (EPS) estimates for shares of Epizyme in a research note issued on Wednesday. SunTrust Banks analyst P. Lawson now anticipates that the biopharmaceutical company will post earnings per share of ($2.20) for the year, up from their previous estimate of ($2.34). SunTrust Banks also issued estimates for Epizyme’s Q4 2017 earnings at ($0.54) EPS, Q1 2018 earnings at ($0.55) EPS, Q2 2018 earnings at ($0.60) EPS, Q3 2018 earnings at ($0.64) EPS, Q4 2018 earnings at ($0.70) EPS, FY2018 earnings at ($2.49) EPS, FY2019 earnings at ($2.98) EPS, FY2020 earnings at ($1.39) EPS and FY2021 earnings at $0.99 EPS.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/11/06/fy2017-eps-estimates-for-epizyme-inc-increased-by-analyst-epzm.html.
Several other analysts have also recently commented on EPZM. Leerink Swann reaffirmed an “outperform” rating and issued a $22.00 target price (down previously from $28.00) on shares of Epizyme in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Royal Bank Of Canada cut Epizyme from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $20.00 to $16.00 in a research report on Thursday. Cann reaffirmed a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research report on Thursday. Finally, BidaskClub raised Epizyme from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $22.67.
Shares of Epizyme (EPZM) opened at $14.20 on Monday.
In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $16.81, for a total transaction of $252,150.00. Following the transaction, the insider now directly owns 23,123 shares in the company, valued at $388,697.63. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 45,000 shares of company stock worth $733,950. Corporate insiders own 25.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new position in shares of Epizyme in the first quarter worth about $175,000. BB&T Securities LLC bought a new position in shares of Epizyme in the second quarter worth about $181,000. Trexquant Investment LP bought a new position in shares of Epizyme in the second quarter worth about $184,000. Finally, SG Americas Securities LLC increased its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 6,072 shares during the period. Institutional investors and hedge funds own 72.20% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
What are top analysts saying about Epizyme Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Epizyme Inc. and related companies.